AtlasXomics

Pre-clinical

New Haven, United StatesFounded 2017atlasxomics.com

AtlasXomics is a spatial biology company focused on bridging epigenomics and pathology to transform biomedical discovery. The company's core technology, DBiT-seq, is a spatial barcoding platform that enables multi-modal mapping of the epigenome and transcriptome at cellular resolution. With validation from over 170 labs worldwide and publications in top-tier journals, AtlasXomics is positioned as a leader in the emerging spatial epigenomics field, offering both innovative assay kits and a code-free bioinformatics pipeline to democratize access to this complex data.

Founded

2017

Focus

Genetics & Genomics

AI Company Overview

Technology Platform

The DBiT-seq platform is a spatial barcoding technology that uses microfluidics to enable high-resolution, multi-modal mapping of the epigenome (chromatin accessibility, histone modifications, DNA methylation) and transcriptome within intact tissue architecture, including FFPE samples.

Funding History

Total raised: $4.2M

Seed$4.2MUndisclosedMay 15, 2020

Opportunities

The primary growth opportunity lies in establishing spatial epigenomics as a standard tool in translational research and drug discovery, particularly within biopharma.

Expanding the assay menu (e.g., full spatial methylome) and enabling larger, cohort-scale studies will drive adoption.

Strategic partnerships with diagnostic companies to develop clinical spatial epigenomic assays represent a long-term, high-value opportunity.

Risk Factors

Key risks include slower-than-expected market adoption of a novel technology, competition from larger, well-funded spatial genomics companies expanding into epigenomics, and the operational challenges of scaling manufacturing and data processing for a complex platform technology.

The company's success is also tied to continued access to capital.

Competitive Landscape

Main competitors are large spatial transcriptomics companies (10x Genomics, NanoString) who currently lack native epigenomic capabilities, and traditional epigenomics kit providers who lack spatial context. AtlasXomics differentiates through its first-mover advantage, true multi-omic co-profiling on a single platform, and unique compatibility with archived FFPE tissues, which is critical for clinical research.